Cargando…

An Open–Label, Randomized, Multi–Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin–2) and Ipilimumab (Yervoy) in Patients with Metastatic Melanoma

Combination immunotherapy with sequential administration may enhance metastatic melanoma (MM) patients with long-term disease control. High Dose Aldesleukin/Recombinant Interleukin-2 (HD rIL-2) and ipilimumab (IPI) offer complementary mechanisms against MM. This phase IV study assessed the sequenced...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hasanov, Merve, Milton, Denái R., Sharfman, William H., Taback, Bret, Cranmer, Lee D., Daniels, Gregory A, Flaherty, Lawrence, Hallmeyer, Sigrun, Milhem, Mohammed, Feun, Lynn, Hauke, Ralph, Doolittle, Gary, Gregory, Nancy, Patel, Sapna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510610/ https://www.ncbi.nlm.nih.gov/pubmed/34650833 http://dx.doi.org/10.1080/2162402X.2021.1984059

Ejemplares similares

Open-label, randomized, multi-center study comparing the sequence of high dose Aldesleukin (Proleukin(® )(HD IL-2) and Ipilimumab Yervoy(® )) in patients with metastatic melanoma (proclivity 02)
por: Patel, Sapna, et al.
Publicado: (2014)

A multi-center study of high dose Aldesleukin (Proleukin(® )(HD IL-2) + Vemurafenib Zelboraf(® )) therapy in patients with BRAF(V600 )mutation positive metastatic melanoma (proclivity 01)
por: Clark, Joseph, et al.
Publicado: (2014)

Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma: the phase 1b MITCI study
por: Curti, Brendan D, et al.
Publicado: (2022)

Update on use of aldesleukin for treatment of high-risk metastatic melanoma
por: Amaria, Rodabe N, et al.
Publicado: (2015)

A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma
por: Buchbinder, Elizabeth I., et al.
Publicado: (2016)

European Medicines Agency extension of indication to include the combination immunotherapy cancer drug treatment with nivolumab (Opdivo) and ipilimumab (Yervoy) for adults with intermediate/poor-risk advanced renal cell carcinoma
por: Ali, Sahra, et al.
Publicado: (2020)

High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014
por: Dutcher, Janice P, et al.
Publicado: (2014)

Immuno-inflammatory in vitro hepatotoxicity models to assess side effects of biologicals exemplified by aldesleukin
por: Roser, Luise A., et al.
Publicado: (2023)

Real‐world treatment practice in patients with advanced melanoma in the era before ipilimumab: results from the IMAGE study
por: Middleton, Mark R., et al.
Publicado: (2016)

Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma
por: Chesney, Jason, et al.
Publicado: (2019)

Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIM(SM)
por: Clark, Joseph I., et al.
Publicado: (2016)

Colonic ulcerations may predict steroid-refractory course in patients with ipilimumab-mediated enterocolitis
por: Jain, Animesh, et al.
Publicado: (2017)

Ipilimumab Pharmacotherapy in Patients with Metastatic Melanoma
por: Jeter, Joanne M., et al.
Publicado: (2012)

Profile of ipilimumab and its role in the treatment of metastatic melanoma
por: Patel, Sapna P, et al.
Publicado: (2011)

Unmasking of intracranial metastatic melanoma during ipilimumab/nivolumab therapy: case report and literature review
por: McDonald, Marin A., et al.
Publicado: (2018)

Adjuvant Ipilimumab in High-Risk Uveal Melanoma
por: Fountain, Eric, et al.
Publicado: (2019)

Ipilimumab
Publicado: (2012)

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
por: Wolchok, Jedd D., et al.
Publicado: (2022)

High-Dose Radiation as a Dramatic, Immunological Primer in Locally Advanced Melanoma
por: Mohiuddin, Majid, et al.
Publicado: (2015)

Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase 2a randomised, double-blind, placebo-controlled trial
por: Camu, William, et al.
Publicado: (2020)

Management of Breast Cancer during Pregnancy: Are We Compliant with Current Guidelines?
por: Shlensky, Victoria, et al.
Publicado: (2017)

Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial
por: Chesney, Jason A, et al.
Publicado: (2023)

Case Report: Neuromyelitis Optica After Treatment of Uveal Melanoma With Nivolumab and Ipilimumab
por: Khimani, Karima, et al.
Publicado: (2022)

Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218)
por: Hodi, F. Stephen, et al.
Publicado: (2020)

Managing Ipilimumab-Induced Hypophysitis: Challenges and Current Therapeutic Strategies
por: Tsoli, Marina, et al.
Publicado: (2020)

Effects of tamoxifen on urinary incontinence: Case report and review of literature
por: Hasanov, Elshad, et al.
Publicado: (2017)

A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma
por: Clark, Joseph I., et al.
Publicado: (2018)

Ipilimumab: Melanoma and beyond
por: Patel, Vishal, et al.
Publicado: (2011)

Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte‐macrophage colony‐stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma
por: Andtbacka, Robert H. I., et al.
Publicado: (2016)

Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines
por: Klein, Christian, et al.
Publicado: (2017)

Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
por: Chapman, Paul B, et al.
Publicado: (2021)

Use of ipilimumab in the treatment of melanoma
por: Acharya, Utkarsh H, et al.
Publicado: (2013)

Ipilimumab-induced colonic perforation
por: Burdine, Lyle, et al.
Publicado: (2014)

Ipilimumab-Induced Neutropenia in Melanoma
por: Ban-Hoefen, Makiko, et al.
Publicado: (2016)

Ipilimumab induced digital vasculitis
por: Padda, Amrita, et al.
Publicado: (2018)

Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study
por: Dalle, Stéphane, et al.
Publicado: (2021)

Ipilimumab in patients with melanoma and autoimmune disease
por: Kyi, Chrisann, et al.
Publicado: (2014)

Infectious Colitis Associated With Ipilimumab Therapy
por: McCutcheon, Jessica L., et al.
Publicado: (2014)

Ipilimumab: A tale of twists and turns
por: Abhyankar, Dhiraj
Publicado: (2018)

Ipilimumab (Immune Checkpoint Inhibitors) Hypophysitis
por: Stagnetto, Margot, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_01d2lgn5il1udis8p157sv4etg